OSI reports OSI-774 data

OSIP and partners Genentech (DNA) and Roche (SWX:ROCZ) updated previously reported data from two Phase II studies of OSI-774 oral small molecule inhibitor of the epidermal growth factor receptor ( EGFR) in advanced refractory non-small cell lung cancer and head and neck cancer. In the 57-patient lung cancer study, 15 patients had disease stabilization, with one complete response and 8 partial responses after at least three months. Median survival was 257 days. In the 124-patient head and neck trial, 7 patients showed partial responses, and 49 patients showed disease stabilization. OSIP said that the number of partial responses was lower than the previously reported 10 patients, resulting from reclassification of certain partial responses as stable disease following third party assessment of imaging data (see BioCentury, Nov. 13, 2000). ...